Literature DB >> 22445732

Risk factors for clinical failure in patients hospitalized with cellulitis and cutaneous abscess.

Jenana Halilovic1, Brett H Heintz, Jennifer Brown.   

Abstract

OBJECTIVE: The objective of this study was to evaluate clinical outcomes and risk factors associated with clinical failure in patients hospitalized with cellulitis with or without abscess.
METHODS: We performed a retrospective cohort study among adults admitted for cellulitis/cutaneous abscess from July 1, 2009 through June 30, 2010. Binary univariate and multivariate logistic regression analyses were performed to identify risk factors for clinical failure among evaluable patients.
RESULTS: A total of 210 cases met inclusion criteria. Among 106 evaluable cases, clinical failure occurred in 34 (32.1%) patients. Weight over 100 kg (Odds ratio [OR] = 5.20, P = 0.01), body mass index (BMI) ≥40 (OR 4.10, P = 0.02), inadequate empiric antibiotic therapy (OR = 9.25, P < 0.01), recent antimicrobial therapy (OR = 2.98, P = 0.03), and lower end of antibiotic dosing per treatment guidelines upon discharge (OR = 3.64, P < 0.01) were independent risk factors for clinical failure. Further subgroup analysis demonstrated that morbidly obese patients were at higher risk for clinical failure if they were discharged on a low oral dose of clindamycin or trimethoprim/sulfamethoxazole (P = 0.002).
CONCLUSION: Inappropriate antimicrobial selection and dosing may adversely affect clinical outcomes among patients with cellulitis/cutaneous abscess. Obese individuals may be at particular risk for clinical failure secondary to inadequate dosing of antimicrobial therapy.
Copyright © 2012 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22445732     DOI: 10.1016/j.jinf.2012.03.013

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  16 in total

1.  Adherence to antibiotic guidelines for erysipelas or cellulitis is associated with a favorable outcome.

Authors:  Camille Klotz; Johan Courjon; Céline Michelangeli; Elisa Demonchy; Raymond Ruimy; Pierre-Marie Roger
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-01-26       Impact factor: 3.267

2.  Obesity and Heart Failure as Predictors of Failure in Outpatient Skin and Soft Tissue Infections.

Authors:  Erin L Conway; John A Sellick; Kari Kurtzhalts; Kari A Mergenhagen
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

3.  OPAT for cellulitis: its benefits and the factors that predispose to longer treatment.

Authors:  J Zhang; E Moore; R Bousfield
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-04-15       Impact factor: 3.267

4.  Clinical, diagnostic, and therapeutic features of patients admitted to acute care hospitals with trunk compared to lower limb cellulitis.

Authors:  Anat Zalmanovich; Michael Lishner; Sharon Reisfeld
Journal:  Intern Emerg Med       Date:  2017-06-07       Impact factor: 3.397

5.  Optimization of Antibiotic Selection in the Emergency Department for Adult Skin and Soft Tissue Infections.

Authors:  Alex M Ebied; Paige Antonelli
Journal:  Hosp Pharm       Date:  2020-12-25

6.  Treatment Duration and Associated Outcomes for Skin and Soft Tissue Infections in Patients With Obesity or Heart Failure.

Authors:  Claudia Ihm; Jesse D Sutton; Tristan T Timbrook; Emily S Spivak
Journal:  Open Forum Infect Dis       Date:  2019-05-07       Impact factor: 3.835

7.  Cellulitis in adult patients: A large, multicenter, observational, prospective study of 606 episodes and analysis of the factors related to the response to treatment.

Authors:  Julio Collazos; Belén de la Fuente; Alicia García; Helena Gómez; C Menéndez; Héctor Enríquez; Paula Sánchez; María Alonso; Ian López-Cruz; Manuel Martín-Regidor; Ana Martínez-Alonso; José Guerra; Arturo Artero; Marino Blanes; Javier de la Fuente; Víctor Asensi
Journal:  PLoS One       Date:  2018-09-27       Impact factor: 3.240

8.  A randomized, double-blind, Phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxacin, linezolid or vancomycin.

Authors:  Jeff Kingsley; Purvi Mehra; Laura E Lawrence; Eugenia Henry; Erin Duffy; Sue K Cammarata; John Pullman
Journal:  J Antimicrob Chemother       Date:  2015-12-17       Impact factor: 5.790

9.  Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a Phase 3, double-blind, randomized study.

Authors:  J Pullman; J Gardovskis; B Farley; E Sun; M Quintas; L Lawrence; R Ling; S Cammarata
Journal:  J Antimicrob Chemother       Date:  2017-12-01       Impact factor: 5.790

10.  Evaluation of Skin and Soft Tissue Infection Outcomes and Admission Decisions in Emergency Department Patients.

Authors:  Nicholas Black; Jon W Schrock
Journal:  Emerg Med Int       Date:  2018-06-13       Impact factor: 1.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.